Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study.

Biter S, Bayram E, Köşeci T, İçli MC, Arslan AM, Özalp FR, Sever N, Ünsal A, Altuntaş NM, Seyyar M, Dinç G, Büyükşimşek M, Türker M, Yaslıkaya Ş, Kıdı MM, Aydınalp Camadan Y, Kefeli U, Uzun M, Yıldırım HÇ, Semiz HS, Erman M, Kara İO

Open source

DOI: 10.3390/medicina62091675
Published: 2026 Aug 31
Container: Medicina (Kaunas, Lithuania)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/medicina62091675,
  title = {Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study.},
  author = {Biter S and Bayram E and Köşeci T and İçli MC and Arslan AM and Özalp FR and Sever N and Ünsal A and Altuntaş NM and Seyyar M and Dinç G and Büyükşimşek M and Türker M and Yaslıkaya Ş and Kıdı MM and Aydınalp Camadan Y and Kefeli U and Uzun M and Yıldırım HÇ and Semiz HS and Erman M and Kara İO},
  year = {2026},
  journal = {Medicina (Kaunas, Lithuania)},
  doi = {10.3390/medicina62091675},
  url = {https://doi.org/10.3390/medicina62091675}
}

RIS

TY  - JOUR
TI  - Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study.
AU  - Biter S
AU  - Bayram E
AU  - Köşeci T
AU  - İçli MC
AU  - Arslan AM
AU  - Özalp FR
AU  - Sever N
AU  - Ünsal A
AU  - Altuntaş NM
AU  - Seyyar M
AU  - Dinç G
AU  - Büyükşimşek M
AU  - Türker M
AU  - Yaslıkaya Ş
AU  - Kıdı MM
AU  - Aydınalp Camadan Y
AU  - Kefeli U
AU  - Uzun M
AU  - Yıldırım HÇ
AU  - Semiz HS
AU  - Erman M
AU  - Kara İO
PY  - 2026
JO  - Medicina (Kaunas, Lithuania)
DO  - 10.3390/medicina62091675
UR  - https://doi.org/10.3390/medicina62091675
ER  -

APA

S, B., E, B., T, K., MC, İ., AM, A., FR, Ö., N, S., A, Ü., NM, A., M, S., G, D., M, B., M, T., Ş, Y., MM, K., Y, A. C., U, K., M, U., HÇ, Y., HS, S., M, E., & İO, K. (2026). Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study.. Medicina (Kaunas, Lithuania). https://doi.org/10.3390/medicina62091675

Source records

pubmed · retrieved 2026-09-26T21:50:30.909Z